Pearls

5 Strategies for managing antipsychotic-induced hyperprolactinemia

Author and Disclosure Information

 

References

There is a well-established relationship between antipsychotic treatment and hyperprolactinemia. Most antipsychotics have been linked to increased prolactin levels, and the risk appears to be dose-related.1 Antipsychotic-induced hyperprolactinemia can be asymptomatic, but it also has been associated with several adverse effects, including menstrual irregularity, osteoporosis, gynecomastia, and sexual dysfunction. Here I discuss what to do before starting a patient on an antipsychotic, and 5 treatment strategies for addressing antipsychotic-induced hyperprolactinemia.

Get a baseline prolactin level

Before starting a patient on an antipsychotic, obtain a baseline prolactin level measurement. If the patient later develops hyperprolactinemia, having a baseline measurement will make it easier to determine if the antipsychotic is a potential cause. Also, it is helpful to gather additional information regarding baseline psychosexual function and menstruation before starting an antipsychotic.

The Table2 shows normal prolactin level ranges for men and women. Antipsychotics tend to raise prolactin levels to a mild or moderate degree, by up to 100 ng/mL (2,000 IU). Generally, the diagnosis of pituitary tumor is more likely when a prolactin level is >118 ng/mL (2,500 mIU/L) in the absence of breastfeeding or pregnancy.3


It is critical to determine if a temporal relationship exists between exposure to an antipsychotic and increase in prolactin levels.3 If the time course is unclear, laboratory tests need to be performed, including assessing liver, renal, and thyroid function or imaging of the pituitary gland. Also, hyperprolactinemia should not be diagnosed based on a single blood test result, because emotional and physical stress can elevate prolactin levels.

Continued to: 5 strategies for addressing hyperprolactinemia

Pages

Recommended Reading

Paliperidone palmitate: Adjusting dosing intervals and measuring serum concentrations
MDedge Psychiatry
Address physical health risks of people with SMI
MDedge Psychiatry
Childhood change of residence raises psychoses risk in young adults
MDedge Psychiatry
Mental illness and the criminal justice system: Reducing the risks
MDedge Psychiatry
It takes guts to be mentally ill: Microbiota and psychopathology
MDedge Psychiatry
Receptor occupancy and drug response: Understanding the relationship
MDedge Psychiatry
Maternal infanticide and postpartum psychosis
MDedge Psychiatry
FDA review supports Nuplazid’s safety
MDedge Psychiatry
Preventing brain damage in psychosis
MDedge Psychiatry
Vitamin B6 for tardive dyskinesia?
MDedge Psychiatry